Medicrown Pharma develops breakthrough therapies rooted in rigorous science. From laboratory discovery to patient outcomes, we are committed to transforming lives across the globe.
Founded in 2004, Medicrown Pharma has grown from a small research laboratory into a globally recognised pharmaceutical leader spanning five therapeutic areas.
We believe that every patient deserves access to the most effective treatments — that belief drives every decision we make.
State-of-the-art labs across 12 global research centres with 4,000+ scientists.
FDA, EMA, and WHO-approved manufacturing with first-pass approval track record.
Compassionate access programmes and tiered pricing ensure no patient is left behind.
Next-generation targeted therapies addressing solid tumours and haematologic malignancies.
Learn more →Comprehensive cardiovascular risk management backed by landmark clinical trials.
Learn more →Disease-modifying treatments for CNS disorders including Parkinson's and MS.
Learn more →Rapid-response antiviral and antibacterial agents for emerging pathogens.
Learn more →14 orphan drug designations targeting unmet needs with small-molecule approaches.
Learn more →mRNA and adjuvanted vaccine technologies for seasonal and pandemic diseases.
Learn more →Our pipeline reflects decades of disciplined investment in translational science. 47 active programmes across all stages of development.
Medicrown's oncology portfolio has fundamentally changed how we manage difficult haematologic cases. The clinical data is robust and the support unmatched.
The scientific rigour behind NeuroPath is evident at every stage. As a neurologist, I trust the evidence base and have seen meaningful outcomes in my MS patients.
From regulatory submissions to post-market pharmacovigilance, Veridian sets the gold standard for how a responsible pharmaceutical company should operate.